Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Returns Long-Acting Growth Hormone Candidate To Altus

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech/Roche anti-cancer drug Avastin wins European approval for first-line use in advanced kidney cancer.

You may also be interested in...

In Narrow Vote, ODAC Votes Against Avastin In Breast Cancer

Oncologic Drugs Advisory Committee expresses concerns about overall survival, toxicity and study conduct.

Genentech Will Develop Long-Acting Growth Hormone Under Licensing Deal With Altus

The growth hormone candidate offers once-weekly dosing for adults and children.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts